Melanoma patients exhibited a 20-fold increase in plasma PlGF levels, and interestingly, a bevacizumab-containing chemotherapy regimen led to a reduction in VEGF-A levels and a further increase in PlGF levels [34]. This evidence concerns the gene PGF and melanoma.